Drug Search Results
More Filters [+]

Falnidamol

Alternative Names: falnidamol, bibx-1382, bibx 1382, bibx1382
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: EORTC
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Falnidamol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EORTC-16981

P1

Suspended

Oncology Solid Tumor Unspecified

None

Recent News Events